New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...

The agreement gives Chiesi exclusive rights for the development and commercialisation of ABO-101 to treat PH1.

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

A research team in Japan has developed an innovative system that can accurately detect genetic mutations in brain tumors ...

Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene ...

The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...

Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications Promega ...

Opportunities in the COVID-19 diagnostics market include growing demand for rapid and precise diagnostic tests, especially mass and molecular diagnostics, innovation in at-home testing kits, and ...